Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MIRM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Maralixibat FDA approved Sep 2021 · Livmarli |
Alagille Syndrome | Phase 4 · NCT07290257 | Recruiting |
| Cholic Acid FDA approved Mar 2015 · Cholbam |
Bile Acid Synthesis Defect | Phase 3 · NCT01438411 | Completed |
| Blinded CDCA 250 mg TID | CTX | Phase 3 · NCT04270682 | Completed |
| Brelovitug | Chronic Hepatitis D | Phase 2/3 · NCT07454837 | Recruiting |
| CDCA Weight-Based Dose TID | CTX | Phase 3 · NCT04270682 | Completed |
| Rescue Medication CDCA 250 mg TID | CTX | Phase 3 · NCT04270682 | Completed |
| Open-Label CDCA 250 mg TID | CTX | Phase 3 · NCT04270682 | Completed |
| LUM001 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 2 · NCT02057718 | Completed |
| Volixibat | Primary Biliary Cholangitis | Phase 2 · NCT05050136 | Active not recruiting |
| Middle Dose of MRM-3379 | Fragile X Syndrome | Phase 2 · NCT07209462 | Recruiting |
| Ursodiol | PBC | Phase 2 · NCT01904058 | Completed |
| Low dose of MRM-3379 Open-Label | Fragile X Syndrome | Phase 2 · NCT07209462 | Recruiting |
| High dose of MRM-3379 | Fragile X Syndrome | Phase 2 · NCT07209462 | Recruiting |
| [14C]-MRM-3379 | Healthy Volunteers | Phase 1 · NCT07712718 | Completed |
Also used in these trials (approved or third-party drugs, not MIRM's own candidates): Bulevirtide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MIRM holds $669.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.3M/quarter from operations, an estimated runway of 82.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MIRM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | Institution (13F) | 7,679,684 | 11.76% | 2026-09-30 |
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 5,537,330 | 8.48% | 2026-09-30 |
| Patrick J Heron Director · +5,752 options |
Insider | 4,031,625 | 6.18% | 2026-01-23 |
| FMR LLC | Institution (13G, 5%+) | 3,777,851 | 5.79% | 2026-06-30 |
| James N. Topper | 5%+ holder (13D) | 3,735,220 | 5.72% | 2025-11-01 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,465,559 | 5.31% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 2,633,578 | 4.03% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 2,544,392 | 3.90% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,498,555 | 3.83% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 2,390,681 | 3.66% | 2026-09-30 |
| Wellington Management Group, LLP | Institution (13F) | 1,688,453 | 2.59% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 1,534,501 | 2.35% | 2026-09-30 |
Share count 65,282,044 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-11 filed 2026-11-13 |
Brege Laura |
Option exercise (M) | 14,167 | $16.71 | 29,870 |
| 2026-11-11 filed 2026-11-13 |
Brege Laura |
Sale (S) | 10,907 | $94.05 | 18,963 |
| 2026-11-11 filed 2026-11-13 |
Brege Laura |
Sale (S) | 3,260 | $94.74 | 15,703 |
| 2026-11-11 filed 2026-11-13 |
Brege Laura |
Option exercise (M) | 14,167 | – | – |
| 2026-11-04 filed 2026-11-04 |
Peetz Christopher |
Option exercise (M) | 20,000 | $2.94 | 226,637 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-09-26 | Atebrioz (zilurgisertib) | NDA | -8.9% | — | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MIRM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →